197 related articles for article (PubMed ID: 19191863)
1. Reduction in labile plasma iron during treatment with deferasirox, a once-daily oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia.
Daar S; Pathare A; Nick H; Kriemler-Krahn U; Hmissi A; Habr D; Taher A
Eur J Haematol; 2009 Jun; 82(6):454-7. PubMed ID: 19191863
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia: the ESCALATOR study.
Taher A; El-Beshlawy A; Elalfy MS; Al Zir K; Daar S; Habr D; Kriemler-Krahn U; Hmissi A; Al Jefri A
Eur J Haematol; 2009 Jun; 82(6):458-65. PubMed ID: 19187278
[TBL] [Abstract][Full Text] [Related]
3. Improved efficacy and tolerability of oral deferasirox by twice-daily dosing for patients with transfusion-dependent β-thalassemia.
Chang HH; Lu MY; Liao YM; Lin PC; Yang YL; Lin DT; Chiou SS; Jou ST; Lin KH; Chang TT
Pediatr Blood Cancer; 2011 Mar; 56(3):420-4. PubMed ID: 21072825
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of deferasirox at low and high iron burdens: results from the EPIC magnetic resonance imaging substudy.
Porter JB; Elalfy MS; Taher AT; Aydinok Y; Chan LL; Lee SH; Sutcharitchan P; Habr D; Martin N; El-Beshlawy A
Ann Hematol; 2013 Jan; 92(2):211-9. PubMed ID: 23086508
[TBL] [Abstract][Full Text] [Related]
5. Simultaneous Determination of Plasma Deferasirox and Deferasirox-Iron Complex Using an HPLC-UV System and Pharmacokinetics of Deferasirox in Patients With β-Thalassemia Major: Once-daily Versus Twice-daily Administration.
Lu MY; Wang N; Wu WH; Lai CW; Kuo PH; Chiang PH; Lin KH; Wu TH
Clin Ther; 2015 Aug; 37(8):1751-60. PubMed ID: 26093827
[TBL] [Abstract][Full Text] [Related]
6. Combined chelation therapy with deferasirox and deferoxamine in thalassemia.
Lal A; Porter J; Sweeters N; Ng V; Evans P; Neumayr L; Kurio G; Harmatz P; Vichinsky E
Blood Cells Mol Dis; 2013 Feb; 50(2):99-104. PubMed ID: 23151373
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of Deferasirox for the treatment of iron overload in Chinese thalassaemia major patients: results from a prospective, open-label, multicentre clinical trial.
Lai YR; Liu RR; Li CF; Huang SL; Li Q; Habr D; Martin N; Shen ZX
Transfus Med; 2013 Dec; 23(6):389-96. PubMed ID: 24147622
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic efficacy of different iron chelators in Egyptian children with Beta Thalassemia with iron overload.
Hagag AA; Hamam MA; Taha OA; Hazaa SM
Infect Disord Drug Targets; 2015; 15(2):98-105. PubMed ID: 26205801
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia.
Pennell DJ; Porter JB; Cappellini MD; El-Beshlawy A; Chan LL; Aydinok Y; Elalfy MS; Sutcharitchan P; Li CK; Ibrahim H; Viprakasit V; Kattamis A; Smith G; Habr D; Domokos G; Roubert B; Taher A
Blood; 2010 Mar; 115(12):2364-71. PubMed ID: 19996412
[TBL] [Abstract][Full Text] [Related]
10. Deferasirox treatment of iron-overloaded chelation-naïve and prechelated patients with myelodysplastic syndromes in medical practice: results from the observational studies eXtend and eXjange.
Gattermann N; Jarisch A; Schlag R; Blumenstengel K; Goebeler M; Groschek M; Losem C; Procaccianti M; Junkes A; Leismann O; Germing U
Eur J Haematol; 2012 Mar; 88(3):260-8. PubMed ID: 22023452
[TBL] [Abstract][Full Text] [Related]
11. Improved treatment satisfaction and convenience with deferasirox in iron-overloaded patients with beta-Thalassemia: Results from the ESCALATOR Trial.
Taher A; Al Jefri A; Elalfy MS; Al Zir K; Daar S; Rofail D; Baladi JF; Habr D; Kriemler-Krahn U; El-Beshlawy A
Acta Haematol; 2010; 123(4):220-5. PubMed ID: 20424435
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of deferasirox estimated by serum ferritin and labile plasma iron levels in patients with aplastic anemia, myelodysplastic syndrome, or acute myeloid leukemia with transfusional iron overload.
Kim IH; Moon JH; Lim SN; Sohn SK; Kim HG; Lee GW; Kim YS; Lee HS; Kwon KY; Kim SH; Park KT; Chung JS; Lee WS; Lee SM; Hyun MS; Kim H; Ryoo HM; Bae SH; Joo YD
Transfusion; 2015 Jul; 55(7):1613-20. PubMed ID: 25764017
[TBL] [Abstract][Full Text] [Related]
13. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload.
Piga A; Galanello R; Forni GL; Cappellini MD; Origa R; Zappu A; Donato G; Bordone E; Lavagetto A; Zanaboni L; Sechaud R; Hewson N; Ford JM; Opitz H; Alberti D
Haematologica; 2006 Jul; 91(7):873-80. PubMed ID: 16818273
[TBL] [Abstract][Full Text] [Related]
14. Deferasirox (Exjade) significantly improves cardiac T2* in heavily iron-overloaded patients with beta-thalassemia major.
Pathare A; Taher A; Daar S
Ann Hematol; 2010 Apr; 89(4):405-9. PubMed ID: 19798501
[TBL] [Abstract][Full Text] [Related]
15. Cost effectiveness of once-daily oral chelation therapy with deferasirox versus infusional deferoxamine in transfusion-dependent thalassaemia patients: US healthcare system perspective.
Delea TE; Sofrygin O; Thomas SK; Baladi JF; Phatak PD; Coates TD
Pharmacoeconomics; 2007; 25(4):329-42. PubMed ID: 17402805
[TBL] [Abstract][Full Text] [Related]
16. Deferasirox-Iron Complex Formation Ratio as an Indicator of Long-term Chelation Efficacy in β-Thalassemia Major.
Lu MY; Lin TH; Chiang PH; Kuo PH; Wang N; Wu WH; Lin KH; Wu TH
Ther Drug Monit; 2017 Apr; 39(2):185-191. PubMed ID: 28141745
[TBL] [Abstract][Full Text] [Related]
17. Prospective assessment of effects on iron-overload parameters of deferasirox therapy in patients with myelodysplastic syndromes.
Greenberg PL; Koller CA; Cabantchik ZI; Warsi G; Glynos T; Paley C; Schiffer C
Leuk Res; 2010 Dec; 34(12):1560-5. PubMed ID: 20615548
[TBL] [Abstract][Full Text] [Related]
18. Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major.
Galanello R; Piga A; Forni GL; Bertrand Y; Foschini ML; Bordone E; Leoni G; Lavagetto A; Zappu A; Longo F; Maseruka H; Hewson N; Sechaud R; Belleli R; Alberti D
Haematologica; 2006 Oct; 91(10):1343-51. PubMed ID: 17018383
[TBL] [Abstract][Full Text] [Related]
19. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia.
Cappellini MD; Cohen A; Piga A; Bejaoui M; Perrotta S; Agaoglu L; Aydinok Y; Kattamis A; Kilinc Y; Porter J; Capra M; Galanello R; Fattoum S; Drelichman G; Magnano C; Verissimo M; Athanassiou-Metaxa M; Giardina P; Kourakli-Symeonidis A; Janka-Schaub G; Coates T; Vermylen C; Olivieri N; Thuret I; Opitz H; Ressayre-Djaffer C; Marks P; Alberti D
Blood; 2006 May; 107(9):3455-62. PubMed ID: 16352812
[TBL] [Abstract][Full Text] [Related]
20. Deferasirox pharmacokinetic evaluation in β-thalassaemia paediatric patients.
Allegra S; Cusato J; De Francia S; Pirro E; Massano D; Piga A; D'Avolio A
J Pharm Pharmacol; 2017 May; 69(5):525-528. PubMed ID: 27230486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
